Abstract
Benign prostatic hyperplasia (BPH) is a common condition in aging men that is characterized bynonmalignant enlargement of the prostate gland, and is frequently accompanied by urinary obstruction, andlower urinary tract symptoms (LUST). Currently pharmacotherapy of BPH is based on two classes of drugs: α1-adrenoceptor (α1-AR) antagonists and α5-reductase inhibitors. It has been shown that α1-AR antagonistsreduce symptom scores and increase peak urinary flow rates in BPH. Of particular importance for BPH therapyare uroselective α1-AR antagonists for which the hypotensive related side-effect caused by α1-AR blockade isreduced. α5-Reductase inhibitors reduce prostate volume and symptom scores, while increasing peak urinaryflow rates. This review describes new α1-AR antagonists and 5α-reductase inhibitors in the treatment of BPH.The new α1-AR antagonists represent various structures such as quinazolines, phenylethylamines, piperidines,and arylpiperazines.5α-Redu ctase inhibitors are classified into two groups: steroidal and non-steroidal. Thenewer non-steroidal inhibitors include derivatives of benzo[c]quinolizinones, benzo[f]quinolonones,piperidones and carboxylic acids. Besides the development of new compounds belonging to the abovementioned groups, new agents for BPH treatment are sought among combined 5α-reductase/α1-AR inhibitors,endothelins, androgen receptors antagonists, growth factors, estrogens and phosphodiesterase isoenzymes aswell as several phytomedicines, used for prevention and treatment of prostate disorders. These new agents canbe used for the design of future targets and development of new drugs in the treatment of BPH. The discoveryof a number of active leads may also ultimately help in developing new safe and effective drugs.
Keywords: Benign prostatic hyperplasia, a1α-adrenoceptor antagonists, 5α-reductase inhibitors
Current Medicinal Chemistry
Title: Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
Volume: 13 Issue: 28
Author(s): Katarzyna Kulig and Barbara Malawska
Affiliation:
Keywords: Benign prostatic hyperplasia, a1α-adrenoceptor antagonists, 5α-reductase inhibitors
Abstract: Benign prostatic hyperplasia (BPH) is a common condition in aging men that is characterized bynonmalignant enlargement of the prostate gland, and is frequently accompanied by urinary obstruction, andlower urinary tract symptoms (LUST). Currently pharmacotherapy of BPH is based on two classes of drugs: α1-adrenoceptor (α1-AR) antagonists and α5-reductase inhibitors. It has been shown that α1-AR antagonistsreduce symptom scores and increase peak urinary flow rates in BPH. Of particular importance for BPH therapyare uroselective α1-AR antagonists for which the hypotensive related side-effect caused by α1-AR blockade isreduced. α5-Reductase inhibitors reduce prostate volume and symptom scores, while increasing peak urinaryflow rates. This review describes new α1-AR antagonists and 5α-reductase inhibitors in the treatment of BPH.The new α1-AR antagonists represent various structures such as quinazolines, phenylethylamines, piperidines,and arylpiperazines.5α-Redu ctase inhibitors are classified into two groups: steroidal and non-steroidal. Thenewer non-steroidal inhibitors include derivatives of benzo[c]quinolizinones, benzo[f]quinolonones,piperidones and carboxylic acids. Besides the development of new compounds belonging to the abovementioned groups, new agents for BPH treatment are sought among combined 5α-reductase/α1-AR inhibitors,endothelins, androgen receptors antagonists, growth factors, estrogens and phosphodiesterase isoenzymes aswell as several phytomedicines, used for prevention and treatment of prostate disorders. These new agents canbe used for the design of future targets and development of new drugs in the treatment of BPH. The discoveryof a number of active leads may also ultimately help in developing new safe and effective drugs.
Export Options
About this article
Cite this article as:
Kulig Katarzyna and Malawska Barbara, Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia, Current Medicinal Chemistry 2006; 13 (28) . https://dx.doi.org/10.2174/092986706779010315
DOI https://dx.doi.org/10.2174/092986706779010315 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Triterpenes from Gloeophyllum odoratum as Potential Leads Towards Potent Thrombin Inhibitors
Letters in Drug Design & Discovery Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part I: Principles of Functional Organisation
Current Neuropharmacology Microcirculation in Sepsis: New Perspectives
Current Vascular Pharmacology In Vitro CYP2D Inhibitory Effect and Influence on Pharmacokinetics and Pharmacodynamic Parameters of Metoprolol Succinate by Terminalia arjuna in Rats
Drug Metabolism Letters Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Current Status and Future of Antifungal Therapy for Systemic Mycoses
Recent Patents on Anti-Infective Drug Discovery Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Cyclodextrin Based Nanosponges: A Multidimensional Drug Delivery System and its Biomedical Applications
Current Drug Delivery Annona sp: Plants with Multiple Applications as Alternative Medicine - A Review
Current Bioactive Compounds Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety